We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Innate Pharma SA | NASDAQ:IPHA | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.123 | -4.68% | 2.507 | 2.63 | 3.00 | 2.58 | 2.507 | 2.57 | 1,088 | 21:16:11 |
• |
Yannis Morel, the current EVP, Business Development and Product Portfolio Strategy and member of the Executive Board, broadens his remit to become
EVP, Chief Operating Officer, extending his operational responsibility to the management of research and early development, working with Innate Pharma Chief Scientific Officer Prof. Eric Vivier, and Chief Development Officer, Nicola
Beltraminelli.
|
• |
Dr. Sonia Quaratino, current EVP, Chief Medical Officer is appointed to the Executive Board. Dr. Quaratino joined Innate Pharma in October 2023
bringing over 25 years of experience in basic research, clinical development, and translational medicine, having worked in academia, global large pharmaceuticals, and biotech companies.
|
• |
Arvind Sood joins the Company in a newly created position of EVP, Innate Pharma SA and President of U.S. operations. Mr. Sood is also appointed to the
Executive Board. Based in the United States, Mr. Sood will be responsible for the execution of the Company’s U.S. strategy, helping expand the Company’s investor relations efforts in the United States, and sourcing business development and
corporate development opportunities in the United States, including liaising with academic institutions and clinical key opinion leaders. Mr. Sood joins Innate Pharma most recently from Amgen and has amassed over four decades of experience
within large biopharma companies in areas including commercial operations, investor relations and financial communications. Arvind joins Innate Pharma from Amgen, where he most recently served as vice president, Investor Relations. Prior to
his time at Amgen, Arvind served as senior vice president, Investor Relations and Financial Communications at Aventis S.A. (now Sanofi), based in Paris, France. Arvind also worked at the Upjohn Company (now Pfizer) of Kalamazoo, Michigan,
where he served in several functions including pharmaceutical sales, marketing and investor relations. He obtained his undergraduate degree in Business Administration from Western Michigan University and his master's degree in Business
Administration from Central Michigan University..
|
• |
As previously announced, Hervé Brailly is acting as interim CEO and Chairman of the Executive Board since January 1, 2024, while a permanent successor
is sought. Mr. Brailly was previously Innate Pharma’s Chairman of the Supervisory Board. He is a co-founder of the Company and was previously CEO until December 2016.
|
INNATE PHARMA S.A.
|
|
Date: January 4, 2024
|
By: /s/ Hervé Brailly
|
Name: Hervé Brailly
|
|
Title: Interim Chief Executive Officer and Chairman of the Supervisory Board
|
1 Year Innate Pharma Chart |
1 Month Innate Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions